Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02416206 · OUTCOME

Number of Patients With Progression-free Survival

High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma · Source last updated 2023-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
3 years

Groups in this outcome

BeEAM

Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma BeEAM: BeEAM

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
BeEAM65

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BeEAM37Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        37
denoms
  1. counts
    1. group Id
      OG000
      value
      65
    units
    Participants
groups
  1. description
    Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma BeEAM: BeEAM
    id
    OG000
    title
    BeEAM
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
3 years
title
Number of Patients With Progression-free Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice